Get started
Author

Nikolay Vladimirov Conev

Observed names: Conev, Nikolay, Conev, Nikolay Vladimiroc, Conev, Nikolay Vladimirov, N Conev, N V Conev, N. Conev, N.V. Conev, NV Conev, Nikolay Conev, Nikolay V Conev, Nikolay V. Conev
ORCID: 0000-0001-5267-0354
Observed ORCID: 0000-0001-5267-0354
OpenAlex ID: A5047307982
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
2022 · L. Paz-Ares, Y. Chen, et al. · ESMO Open · 346
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
2023 · Luis Paz-Ares, Marina Chiara Garassino, et al. · Clinical Cancer Research · 57
PDF
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer
2020 · Mila P. Petrova, Mariyana I. Eneva, et al. · BioScience Trends · 56
PDF
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
2022 · Yuanbin Chen, Luis Paz-Ares, et al. · JTO Clinical and Research Reports · 48
PDF
Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients
2015 · Nikolay V. Conev, Ivan S. Donev, et al. · BioScience Trends · 48
PDF
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer
2019 · Nikolay V. Conev, Yavor K. Kashlov, et al. · Clinical and investigative medicine · 42
PDF
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
2020 · M P Petrova, I S Donev, et al. · Clinical & Experimental Immunology · 37
PDF
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
2020 · J.W. Goldman, M.C. Garassino, et al. · Annals of Oncology · 32
PDF
Circulating Histones to Detect and Monitor the Progression of Cancer
2023 · Desislava K. Tsoneva, Martin N. Ivanov, et al. · International Journal of Molecular Sciences · 29
PDF
Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis
2022 · Maria Radanova, Mariya Levkova, et al. · Biomedicines · 21
PDF
New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer
2021 · Maria Radanova, Galya Mihaylova, et al. · International Journal of Molecular Sciences · 21
PDF
PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
2019 · L. Paz-Ares, Y. Chen, et al. · Journal of Thoracic Oncology · 21
Association Between Serum CK-18 Levels and the Degree of Liver Damage in Fructose-Induced Metabolic Syndrome
2018 · Kameliya Bratoeva, Silviya Nikolova, et al. · Metabolic Syndrome and Related Disorders · 16
Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention
2016 · Javor K Kashlov, Ivan S Donev, et al. · BioScience Trends · 16
PDF
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
2020 · Yuanbin Chen, Luis G. Paz-Ares, et al. · Journal of Clinical Oncology · 15
Impact of travel burden on clinical outcomes in lung cancer
2022 · Dragomir Svetozarov Stoyanov, Nikolay Vladimirov Conev, et al. · Supportive Care in Cancer · 14
LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
2021 · L. Paz-Ares, Y. Chen, et al. · Annals of Oncology · 13
PDF
Rare case of ameloblastoma with pulmonary metastases
2017 · Ivan Valkadinov, Nikolay Conev, et al. · Intractable & Rare Diseases Research · 13
PDF
Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer
2021 · Maria Radanova, Galya Mihaylova, et al. · Current Oncology · 11
PDF
Primary Adenoid Cystic Carcinoma of the Skin with Multiple Local Recurrences
2015 · Ivan Dimitrov Tonev, Yana Stoeva Pirgova, et al. · Case Reports in Oncology · 9
PDF
P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
2021 · N. Reinmuth, M.C. Garassino, et al. · Journal of Thoracic Oncology · 7
PDF
Fast time perception is associated with high levels of anxiety in cancer patients prior to starting chemotherapy
2020 · Ivan Shterev Donev, Martina Stoyanova Ivanova, et al. · BioScience Trends · 7
PDF
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
2025 · Niels Reinmuth, Jonathan W. Goldman, et al. · Clinical Lung Cancer · 6
PDF
Works count: 206
Citation count: 6,876
H-index: 16
I10-index: 23
Year
Topic
Type